Last reviewed · How we verify

Botulinum Toxin Type A for Injection — Competitive Intelligence Brief

Botulinum Toxin Type A for Injection (Botulinum Toxin Type A for Injection) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Neurotoxin; neuromuscular blocking agent. Area: Neurology; Dermatology; Aesthetics.

phase 3 Neurotoxin; neuromuscular blocking agent SNAP-25 (synaptosome-associated protein of 25 kDa); acetylcholine release machinery Neurology; Dermatology; Aesthetics Small molecule Live · refreshed every 30 min

Target snapshot

Botulinum Toxin Type A for Injection (Botulinum Toxin Type A for Injection) — Lanzhou Institute of Biological Products Co., Ltd. Botulinum toxin type A blocks acetylcholine release at the neuromuscular junction by cleaving SNARE proteins, causing temporary muscle paralysis.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
Botulinum Toxin Type A for Injection TARGET Botulinum Toxin Type A for Injection Lanzhou Institute of Biological Products Co., Ltd phase 3 Neurotoxin; neuromuscular blocking agent SNAP-25 (synaptosome-associated protein of 25 kDa); acetylcholine release machinery
Botulinum Toxin Type A 900kDa Botulinum Toxin Type A 900kDa Allergan marketed Neurotoxin; acetylcholine release inhibitor SNAP-25 (synaptosome-associated protein of 25 kDa)
Botox infiltration Botox infiltration University Rovira i Virgili marketed Neurotoxin; botulinum toxin type A SNARE complex (synaptosome-associated protein); acetylcholine release machinery
Botulinum Toxin Type A (Botox) Botulinum Toxin Type A (Botox) University of Utah marketed Neurotoxin; neuromuscular blocking agent SNAP-25 (synaptosome-associated protein of 25 kDa)
Botulinum Toxin Type A 900kD Botulinum Toxin Type A 900kD Allergan marketed Neurotoxin; acetylcholine release inhibitor SNAP-25 (synaptosome-associated protein of 25 kDa)
Botulinum toxin A "Botox Cosmetics" Botulinum toxin A "Botox Cosmetics" Croma-Pharma GmbH marketed Neurotoxin; acetylcholine release inhibitor SNARE complex (synaptosome-associated protein); acetylcholine release machinery
Radiesse, Xeomin, Belotero Radiesse, Xeomin, Belotero Main Line Center for Laser Surgery marketed Dermal fillers and neurotoxin

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Neurotoxin; neuromuscular blocking agent class)

  1. Ivo Pitanguy Institute · 1 drug in this class
  2. Lanzhou Institute of Biological Products Co., Ltd · 1 drug in this class
  3. Robert Jones and Agnes Hunt Orthopaedic and District NHS Trust · 1 drug in this class
  4. University of Utah · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Botulinum Toxin Type A for Injection — Competitive Intelligence Brief. https://druglandscape.com/ci/botulinum-toxin-type-a-for-injection. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators: